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The global roll-out of the COVID-19 vaccine is a
cause for celebration. Vaccinations are the most suc-
cessful public health measure in history, saving mil-
lions of lives each year globally, preventing disease
and bringing enormous societal and economic bene-
fits.1 Reversing and mitigating the ongoing damage
wrought by COVID-19 is largely contingent on a suc-
cessful worldwide equitable vaccination strategy.2 An
estimated 60%–70% of the world’s population needs
to be vaccinated to achieve an effective herd
immunity.3,4
One of the biggest hurdles to vaccinations is hesi-
tancy: a delay in acceptance, or refusal despite avail-
ability. We propose five Cs to tackle vaccine
hesitancy: Confidence (importance, safety and effi-
cacy of vaccines); Complacency (perception of low
risk and low disease severity); Convenience (access
issues dependent on the context, time and specific
vaccine being offered5,6); Communications (sources
of information); and Context (sociodemographic
characteristics) (see Figure 1).1
Confidence
Confidence in vaccine safety, efficacy and importance
is crucial, and highlighted by recent concerns about
the possible association between the AstraZeneca and
Johnson & Johnson vaccines and very rare unusual
blood clots such as cerebral venous sinus throm-
bosis.2,7 The public need to understand that these
events are extremely rare (estimated 4/million
people vaccinated), the risk of getting cerebral
venous sinus thrombosis if you contract COVID-19
may be up to 10 times higher than getting it due to
vaccination, and for most people the benefits of vac-
cine vastly outweigh the risk. Other factors affecting
uptake include historic distrust along with underre-
presentation of ethnic minorities in clinical trials, and
religious concerns about the safety and acceptability
of the vaccine. In Muslim-majority countries such as
Indonesia and Malaysia, a drop in confidence in the
vaccine was directly due to religious rulings of vac-
cines being haram (e.g. including unacceptable ingre-
dients derived from pigs or containing alcohol).1 This
year, the month of Ramadan for Muslims is between
April and May. Building confidence in the vaccine
also requires sensitive, non-stigmatising messages
that, for example, the intramuscular injection does
not nullify one’s fast (which is observed dawn to
dusk). Perceptions of vaccine safety and efficacy are
the strongest predictors of vaccine uptake and many
vaccine-hesitant people cite concerns about safety
and side effects.8,9 It is clearly crucial to engage in
transparent dialogue that respects people’s concerns
and acknowledges uncertainty.
Complacency
Complacency is strongly associated with lower vac-
cine uptake. Lower perceptions of personal risk and
disease severity for COVID-19 have been reported in
younger people and individuals of lower socioeco-
nomic status.10 As the lower age groups are being
offered the vaccine, addressing complacency through
repeated risk communication is crucial to facilitate
informed decision making. It is important to
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Figure 1. Tackling COVID-19 vaccine hesitancy with the five Cs.
296 Journal of the Royal Society of Medicine 114(6)
emphasise the greater societal benefits of population
level immunity and the protection it offers to those
vulnerable, their families and friends.
Convenience
Evidence points to the crucial role of well-planned
and convenient vaccination delivery, emphasising
the role of an easy-to-reach location and attention
to financial costs of having the vaccine.1 High vaccin-
ation levels were reported in the US when it took
place at schools11 and similarly a high uptake in the
UK of the influenza vaccine was achieved through
pharmacies and general practices.1,12 However,
recent data from England show that more people
expected a longer wait and more inconvenient vaccin-
ation than they actually experienced.13 Perceptions of
convenience may also need to be addressed.
Communication
According to the World Health Organization, the
world is also fighting an ‘infodemic’ of ‘a few facts,
mixed with fear, speculation and rumour’ which,
within the context of ongoing uncertainties and know-
ledge gaps, has been amplified through technology and
social media platforms. An excessive amount of infor-
mation, rapid changes in COVID-19 information and
guidance, and lack of certainty has causedmisinforma-
tion to spread faster than the infection, thus creating
general distrust and confusion.14Misinformation feeds
on people’s fears and anxieties about the pandemic to
promote anti-vaccination conspiracy theories.15 A
genuine transparent dialogue backed by community
engagement is required to address the public’s con-
cerns and build confidence. It is also important to
acknowledge uncertainties. Social media platforms
should exercisemore accountability and remove harm-
ful andmisinformed content.7,15,16 Lessons learnt from
previous pandemics and immunisation programmes
suggest that vaccine deployment should exploit exist-
ing infrastructure such as primary care, pharmacies
and trusted healthcare professionals.12
Context
Context including ethnicity, religion, occupation and
socioeconomic status is often overlooked. The prob-
lem starts with the term vaccine hesitancy itself.
Although it has been widely used in the literature and
adopted by theWorldHealthOrganization, it does not
take account of the powerful structural factors such as
systemic racism and access barriers which may lead to
low vaccine take-up in some groups. Further, it places
an emphasis on individual agency and implies a degree
of blame. European data show lower intention to be
vaccinated againstCOVID-19 among racial and ethnic
minorities, thosewith lower education, younger people
and people with previously poor compliance with rec-
ommended vaccinations,1,17 with corresponding poor
uptake of COVID-19 vaccines in some ethnic minori-
ties and deprived communities.18 This follows a his-
toric trend19 in the UK, and suggests that COVID-19
has exacerbated inequalities related to ethnicity and
socioeconomic status.20
Conclusions
Vaccine hesitancy is complex, variable and shaped by
multiple contextual factors. Most research has been
conducted in high-income countries and few interven-
tions have been found to be effective in low-income
and middle-income settings.21 It is therefore essential
that along with COVID-19 Vaccines Global Access
(COVAX)22 – a mechanism to fairly distribute
COVID-19 vaccine doses around the world – there
is a concerted international effort to understand, ana-
lyse and overcome vaccine hesitancy.23 International
organisations such as the Red Cross, Red Crescent
and UNICEF have the experience and expertise to
communicate risk during a crisis. Strengthening
local capabilities to mobilise diverse communities by
addressing the five Cs of vaccine hesitancy through
tailored, appealing, culturally competent and
multilingual messages is supported by evidence and
could have the highest chance of success.
Declarations
Competing Interests: None declared.
Funding: MCM receives funding from the Leverhulme Trust,
Leverhulme Centre for Demographic Science and ERC-2018-
ADG-835079.
Ethics approval: Not applicable.
Guarantor: MSR
Contributorship: MSR conceptualised and wrote the manu-
script, incorporated feedback from co-authors and finalised the
manuscript. PO helped with the writing and contributed to the
revision and concepts. AE, CSW, KV and MCM provided feed-
back, edits and contributed to the concept. The final manuscript
was approved by all authors.
Acknowledgements: None.
Provenance: Not commissioned; editorial review
ORCID iD: Mohammad S Razai https://orcid.org/0000-0002-
6671-5557
References
1. Mills M, Rahal C, Brazel D, et al. COVID-19 vaccine
deployment: Behaviour, ethics, misinformation and
Razai et al. 297
policy strategies. London: The Royal Society & The
British Academy 2020.
2. Wise J. Covid-19: rare immune response may cause
clots after AstraZeneca vaccine, say researchers. BMJ
2021; 373: n954.
3. National Academies of Sciences, Engineering, and
Medicine. (2020). Framework for equitable allocation
of COVID-19 vaccine. Retrieved from https://www.
nap.edu/catalog/25917/framework-for-equitable-allo-
cation-of-covid-19-vaccine.
4. Anderson RM, Vegvari C, Truscott J, et al. Challenges
in creating herd immunity to SARS-CoV-2 infection by
mass vaccination. Lancet 2020; 396: 1614–1616.
5. Larson HJ, Jarrett C, Eckersberger E, et al.
Understanding vaccine hesitancy around vaccines and
vaccination from a global perspective: a systematic
review of published literature, 2007–2012. Vaccine
2014; 32: 2150–2159.
6. WHO. 2014 Report on the SAGE Working Group on
Vaccine Hesitancy. Geneva: WHO, 2014.
7. Wilson SL and Wiysonge C. Social media and vaccine
hesitancy. BMJ Global Health 2020; 5: e004206.
8. Kwon Y, Cho HY, Lee YK, et al. Relationship
between intention of novel influenza A (H1N1) vaccin-
ation and vaccination coverage rate. Vaccine 2010; 29:
161–165.
9. Myers LB and Goodwin R. Determinants of adults’
intention to vaccinate against pandemic swine flu.
BMC Public Health 2011; 11: 15.
10. Wolf MS, Serper M, Opsasnick L, et al. Awareness,
attitudes, and actions related to COVID-19 among
adults with chronic conditions at the onset of the U.S
outbreak: a cross-sectional survey. Ann Intern Med
2020; 173: 100–109.
11. Centers for Disease Control and Prevention. Final
Estimates for 2009–10 Seasonal Influenza and
Influenza A (H1N1) 2009 Monovalent Vaccination
Coverage – United States, August 2009 through May,
2010. Atlanta: CDC, 2011.
12. Mills MC and Salisbury D. The challenges of
distributing COVID-19 vaccinations. EClinical
Medicine 2021; 31 Jan; 31: 100674. DOI: 10.1016/
j.eclinm.2020.100674.
13. ONS. Coronavirus and the Social Impacts on Great
Britain: 26 March 2021. UK: ONS, 2021.
14. Zarocostas J. How to fight an infodemic. Lancet 2020;
395: 676.
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